Velpanat Tablet (Sofosbuvir + Velpatasvir)

Rating:

90 % of 100

Sofosbuvir + Velpatasvir is a combination medication used in the treatment of chronic hepatitis C virus (HCV) infection in adults. This fixed-dose combination tablet contains two direct-acting antiviral agents: sofosbuvir and velpatasvir. It is sold under the brand name Epclusa or Velpanat.

Package	QTY	Price	Add To Cart
28 Tablet/s		$399.00
56 Tablet/s		$798.00
84 Tablet/s		$1,195.00

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Velpanat Tablet (Sofosbuvir + Velpatasvir) For Hepatitis C virus

Sofosbuvir + Velpatasvir is a combination medication used in the treatment of chronic Hepatitis C virus (HCV) infection in adults. This fixed-dose combination tablet contains two direct-acting antiviral agents: sofosbuvir and velpatasvir. Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor, while velpatasvir is an NS5A replication complex inhibitor. Together, these drugs work by interfering with the replication of the Hepatitis C virus, ultimately leading to its eradication from the body. The combination of sofosbuvir and velpatasvir has shown high efficacy in treating various genotypes of HCV, making it an important treatment option for patients with chronic hepatitis C. Epclusa is the brand name for the combination medication containing sofosbuvir and velpatasvir.

Sofosbuvir+Velpatasvir Tablet Dosage Forms:

The recommended dosage of Sofosbuvir + Velpatasvir is one tablet (containing 400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily. The tablet can be taken with or without food. The duration of treatment may vary depending on the patient's HCV genotype and medical history. It is important to follow the prescribed dosage and duration of treatment as directed by your healthcare provider.

Sofosbuvir+Velpatasvir Tablet Alternatives:

While Sofosbuvir + Velpatasvir is a highly effective treatment option for chronic hepatitis C, there are alternative medications available, depending on the patient's specific needs and the HCV genotype. Some of the other direct-acting antiviral agents used in the treatment of HCV include:

Glecaprevir + Pibrentasvir (brand name: Mavyret)
Ledipasvir + Sofosbuvir (brand name: Harvoni)
Daclatasvir + Sofosbuvir (brand name: Daklinza + Sovaldi)
Grazoprevir + Elbasvir (brand name: Zepatier)
Velpatasvir + Voxilaprevir (brand name: Vosevi)

It is important to consult with a healthcare professional to determine the most appropriate treatment option based on individual factors such as HCV genotype, medical history, and any existing liver disease. It is important to note that while Sofosbuvir + Velpatasvir can be considered a Life-Saving Drug for individuals with chronic HCV infection, it is not specifically categorized as a life-saving drug for other conditions such as cancer.

Sofosbuvir+Velpatasvir Tablet Benefits

One of the key advantages of the Sofosbuvir+Velpatasvir Tablet is its high cure rates for hepatitis C. Clinical studies have shown that this combination therapy can achieve sustained virologic response (SVR) rates of over 95% in patients with different HCV genotypes. This means that the majority of patients who take this medication can expect to be cured of their infection. Another benefit of the Sofosbuvir+Velpatasvir Tablet is its convenience and simplicity. Unlike older HCV treatments, which often required multiple medications and had complex dosing schedules, this combination therapy comes in a single tablet. This makes it easier for patients to adhere to their treatment regimen, improving the likelihood of successful outcomes. Moreover, Sofosbuvir+Velpatasvir Tablet is generally well-tolerated by most patients. Common side effects are mild and include fatigue, headache, and nausea. Compared to older HCV treatments, which often had more significant side effects, this combination therapy offers a better overall tolerability profile.

Sofosbuvir+Velpatasvir Tablet cost: If you are interested in checking the cost of the Sofosbuvir+Velpatasvir Tablet, you can visit 1mgstore.com. This online platform provides information on medication prices, allowing you to compare and make informed decisions regarding your healthcare needs.

Some Of The Primary Precautionary Measures To Be Taken While Using Velpanat Tablet (Sofosbuvir + Velpatasvir)

Pregnancy and breast-feeding: Sofosbuvir + Velpatasvir should not be used during pregnancy or while breastfeeding unless specifically recommended by a healthcare professional. It is important to discuss the potential risks and benefits with your doctor before starting treatment.
Hepatitis B co-infection: Sofosbuvir + Velpatasvir/Epclusa should not be used as a monotherapy in patients with hepatitis C and hepatitis B virus (HBV) co-infection. Discontinuation of treatment with Sofosbuvir + Velpatasvir may lead to the reactivation of HBV. Therefore, patients should be closely monitored for signs of HBV reactivation during and after treatment.
Kidney and liver problems: Patients with severe kidney or liver impairment should exercise caution when taking Sofosbuvir + Velpatasvir (Velpanat). Dose adjustments may be necessary, and close monitoring is recommended to ensure the medication is well-tolerated.
Drug resistance: In rare cases, the hepatitis C virus may develop resistance to Sofosbuvir + Velpatasvir or other direct-acting antiviral agents. If treatment failure occurs or if the virus reappears after successful treatment, additional testing and alternative treatment options should be considered.

Key Utilization Must Be Noticed Of Velpanat Tablet (Sofosbuvir + Velpatasvir)

Sofosbuvir + Velpatasvir is primarily used for the treatment of chronic hepatitis C virus (HCV) infection in adults. It is effective against multiple genotypes of HCV, including genotypes 1, 2, 3, 4, 5, and 6. This medication is indicated for both treatment-naïve patients and those who have previously received interferon-based treatment. Sofosbuvir + Velpatasvir/Epclusa is often prescribed as part of a combination therapy regimen and may be used with or without ribavirin, depending on the specific patient characteristics and the severity of the liver disease.

The main goal of treatment with Sofosbuvir + Velpatasvir/Epclusa is to achieve sustained virologic response (SVR), which means the virus becomes undetectable in the blood for at least 12 weeks after completing the treatment. SVR indicates a cure for HCV infection and reduces the risk of long-term complications such as cirrhosis, liver failure, and hepatocellular carcinoma.

Some Of The Secondary Effects Of Velpanat Tablet (Sofosbuvir + Velpatasvir)

Common side effects: The most common side effects associated with Sofosbuvir + Velpatasvir (Velpanat) include headache, fatigue, nausea, diarrhea, and insomnia. These side effects are usually mild and temporary, and they tend to improve as the treatment progresses.
Serious side effects: While rare, serious side effects may occur with Sofosbuvir + Velpatasvir/Epclusa. These can include severe allergic reactions, bradycardia (slow heart rate) when co-administered with amiodarone, and reactivation of hepatitis B virus in patients co-infected with HBV and HCV. Symptoms such as yellowing of the skin or eyes (jaundice), dark urine, pale stools, and persistent fatigue should be reported to a healthcare professional immediately.
Drug-induced liver injury: Cases of drug-induced liver injury have been reported with the use of sofosbuvir-containing regimens. It is important to monitor liver function during treatment, especially in patients with pre-existing liver disease. If signs of liver injury occur, treatment should be discontinued.

Answers to Common Inquiries About Sofosbuvir + Velpatasvir Tablet

Can Sofosbuvir + Velpatasvir Tablet Be Used For The Treatment Of All Genotypes Of Hepatitis C?

Sofosbuvir + Velpatasvir Tablet is effective against multiple genotypes of hepatitis C virus (HCV), including genotypes 1, 2, 3, 4, 5, and 6. It is a pan-genotypic treatment option, meaning it can be used to treat a wide range of HCV genotypes.

Can Sofosbuvir + Velpatasvir Tablet/Epclusa Be Taken With Other Medications?

Sofosbuvir + Velpatasvir Tablet can interact with certain medications, so it is important to inform your healthcare provider about all the medications you are taking. They can assess potential drug interactions and recommend adjustments or alternative treatments if necessary.

Is Sofosbuvir + Velpatasvir Tablet/Epclusa Safe For Patients With Kidney Or Liver Problems?

Patients with severe kidney or liver impairment should exercise caution when taking Sofosbuvir + Velpatasvir tablets. Close monitoring and potential dose adjustments may be necessary to ensure the medication is well-tolerated.

Can Sofosbuvir + Velpatasvir Tablet (Velpanat) Be Used During Pregnancy?

Sofosbuvir + Velpatasvir Tablet should not be used during pregnancy unless specifically recommended by a healthcare professional. It is important to discuss the potential risks and benefits with your doctor before starting treatment.

How Long Does The Treatment With Sofosbuvir + Velpatasvir Tablet Last?

The duration of treatment with Sofosbuvir + Velpatasvir Tablet may vary depending on the patient's HCV genotype and medical history. Typically, treatment duration can range from 8 to 12 weeks. Your healthcare provider will determine the appropriate treatment duration for you.

Primary Drug Interconnections With Velpanat Tablet (Sofosbuvir + Velpatasvir)

Amiodarone: Co-administration of Sofosbuvir + Velpatasvir with amiodarone, a medication used to treat irregular heart rhythms, may increase the risk of a serious cardiac side effect known as bradycardia. Therefore, the concomitant use of these medications is generally not recommended. If co-administration is necessary, close monitoring of heart function is essential.
Rifampin: Rifampin, an antibiotic used to treat tuberculosis and other infections, may significantly reduce the levels of sofosbuvir and velpatasvir in the body. This can decrease the effectiveness of Sofosbuvir + Velpatasvir (Velpanat), and alternative treatment options should be considered.
Other medications: Sofosbuvir + Velpatasvir/Epclusa has the potential to interact with various medications, including certain anticonvulsants, antifungal agents, HIV protease inhibitors, and some cholesterol-lowering drugs. It is important to inform your healthcare provider about all the medications you are taking to ensure their safe and effective co-administration.